Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in People ≥ 65 Years Old with Type 2 Diabetes and Mild Renal Insufficiency

• Published in: Diabetes therapy 2020-10, Vol.11 (10), p.2419-2428
• Main Authors: Raji, Annaswamy, Xu, Zhi Jin, Lam, Raymond L. H., O’Neill, Edward A., Kaufman, Keith D., Engel, Samuel S.
• Format: Article
• Language: English
• Subjects: Aged patients; Antidiabetics; Brief Report; Cardiology; Clinical outcomes; Comparative analysis; Dapagliflozin; Diabetes; Diabetic nephropathies; Diabetic nephropathy; Drug therapy; Endocrinology; Hyperglycemia; Internal Medicine; Kidney diseases; Kidney failure; Medicine; Medicine & Public Health; Older people; Patient outcomes; Patient safety; Sitagliptin; Type 2 diabetes
• ISSN: 1869-6953; 1869-6961
• DOI: 10.1007/s13300-020-00907-w

Introduction Older patients with type 2 diabetes (T2D) are at increased risk of diabetic nephropathy and mild renal insufficiency. This analysis compared the anti-hyperglycemic efficacy and safety of sitagliptin with dapagliflozin in patients ≥ 65 years of age with T2D and mild renal insufficiency. Methods This was a post hoc analysis of data from 410 patients ≥ 65 years old who participated in a 24-week, randomized, double-blind clinical trial (CompoSIT-R [comparison of sitagliptin with dapagliflozin in mild renal impairment]; NCT02532855) in T2D patients with mild renal insufficiency and on metformin ± a sulfonylurea; the primary efficacy end point was change in HbA1c at week 24. Results Treatment groups were well balanced at baseline (mean HbA1c = 7.7/7.7% and eGFR = 79/76 ml/min/1.73 m 2 for sitagliptin/dapagliflozin). At week 24, LS mean (95% CI) change in HbA1c and percentage of patients with HbA1c